2020 EBMT Meeting Reporter | Supplements And Featured Publications

Transplantation Using Haploidentical Donors Outperforms Matched Sibling Donors in MRD+ ALL

September 09, 2020

Haploidentical donor transplantation led to stronger anti-leukemia activity compared with matched sibling donor transplantation in transplant-eligible patients with minimal residual disease–positive acute lymphoblastic leukemia.

Basiliximab Elicits High Response Rates After Haploidentical HSCT in Pediatric Acute GVHD

September 08, 2020

Basiliximab proved to be an effective second-line treatment option for pediatric patients with steroid-refractory acute graft-versus-host disease that developed following haploidentical hematopoietic stem cell transplantation.

Belumosudil Continues to Elicit Statistically Significant Responses in cGVHD

September 02, 2020

The orally available ROCK2 selective inhibitor belumosudil continues to elicit clinically meaningful overall response rates in patients with chronic graft-versus-host disease (cGVHD) who have received ≥2 prior lines of systemic therapy

Blinatumomab Represents a New Standard of Care in Pediatric High-Risk First-Relapse ALL

September 02, 2020

Blinatumomab monotherapy as consolidation therapy prior to allogeneic hematopoietic stem cell transplant resulted a significant improvement in event-free survival and a lower risk of recurrence in children with high-risk B-cell precursor–acute lymphoblastic leukemia.

Addressing Diagnostic Challenges in HSCT-TMA and Exploring Emerging Biomarkers

August 31, 2020

Biomarkers predictive of risk in hematopoietic stem cell transplantation–associated thrombotic microangiopathy have undergone a recent evolution, with several new markers under exploration and many efforts focused on making current markers more precise and accurate to strengthen diagnostic criteria.

Emerging Evidence Supports the Use of Narsoplimab in HSCT-TMA

August 31, 2020

Rafael F. Duarte, MD, PhD, FRCP, presents 2 real-world clinical cases in which the investigational monoclonal antibody narsoplimab demonstrated clinical benefit in patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy.